GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (STU:NJT) » Definitions » Institutional Ownership

Regenetp (STU:NJT) Institutional Ownership : 0.00% (As of Jun. 07, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Regenetp Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Regenetp's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Regenetp's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Regenetp's Float Percentage Of Total Shares Outstanding is 96.51%.


Regenetp Institutional Ownership Historical Data

The historical data trend for Regenetp's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenetp Institutional Ownership Chart

Regenetp Historical Data

The historical data trend for Regenetp can be seen below:

2022-11-30 2022-12-31 2023-01-31 2023-02-28 2023-03-31 2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31
Institutional Ownership 0.64 0.63 0.63 0.63 0.62 0.62 0.62 0.01 0.01 0.01

Regenetp Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Regenetp (STU:NJT) Business Description

Traded in Other Exchanges
Address
1960 South 4250 West, Salt Lake City, UT, USA, 84104
Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.

Regenetp (STU:NJT) Headlines

No Headlines